PolyPid Updates On SHIELD II Trial Amidst KOL Insights On Surgical Site Infection Prevention
Portfolio Pulse from Benzinga Newsdesk
PolyPid provides an update on its SHIELD II trial, which aims to address the rising rates of surgical site infections (SSIs) post-COVID. With 250 out of 600 patients enrolled, an unblinded interim analysis will be conducted after 400 patients complete their 30-day follow-up. Top-line results are expected in Q1 2025.
June 18, 2024 | 11:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PolyPid's SHIELD II trial update indicates progress in addressing rising surgical site infections. With 250 patients enrolled and an interim analysis planned after 400 patients' follow-up, the trial's top-line results are expected in Q1 2025.
The update on the SHIELD II trial shows significant progress in patient enrollment and sets clear expectations for interim and top-line results. This is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100